Dulaglutide vs Noopept
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Dulaglutide
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Full details →Noopept
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a peptide-derived nootropic developed in Russia. While technically a dipeptide prodrug rather than a true peptide, it's often discussed alongside peptide nootropics.
Full details →Side-by-Side Comparison
| Aspect | Dulaglutide | Noopept |
|---|---|---|
| Mechanism | GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression. | Metabolized to cycloprolylglycine which modulates AMPA and NMDA receptors, increases NGF and BDNF expression, and provides neuroprotective effects through antioxidant mechanisms. |
| Typical Dosage | Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response. | Oral: 10-30mg daily, typically divided into 2-3 doses. Sublingual use may enhance absorption. Some users go higher but effects may plateau. |
| Administration | Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens. | Oral or sublingual administration. Unlike most peptides, it's orally bioavailable. Can be taken with or without food. |
| Side Effects | Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration. | Headache (often from choline depletion), irritability, insomnia if taken late, and occasional brain fog during initial use. |
| Best For |